无论基线特征如何,杜皮卢马布在2型喘中的长期疗效
Michael E Wechsler1, Linda Rogers2, G Walter Canonica3,4
1Department of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
ERJ open research
|December 17, 2024
概括
该TRAVERSE研究表明dupilumab有效治疗中度至重度的2型喘长期. 这种生物疗法在患者中表现出持续的疗效,长达96周.
科学领域:
- 过敏和免疫学的过敏和免疫学.
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
背景情况:
- 2型喘是一种慢性炎症性呼吸道疾病.
- 无法控制的中度至重度病例需要先进的治疗选择.
- 针对2型炎症的生物疗法提供了新的治疗途径.
研究的目的:
- 评估dupilumab的长期疗效和安全性.
- 评估dupilumab在广泛患者群体中的有效性.
- 延长喘治疗结果的观察期.
主要方法:
- TRAVERSE研究是一项长期扩展试验.
- 包括患有中度至重度2型喘的患者.
- 评估有效性和安全性长达96周.
主要成果:
- 杜皮卢马布在治疗无法控制的中度至重度2型喘方面表现出持续的疗效.
- 观察到肺功能和喘控制的持续改善.
- 在96周的治疗期间,杜皮卢马布的安全性概况保持一致.
结论:
- 杜皮卢马布在没有控制的中度至重度2型喘患者中提供长期疗效.
- 该疗法在不同患者的人口统计和疾病特征方面是有效的.
- 杜皮卢马布对这一患者群体来说是一个有价值的长期治疗选择.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
241
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
241
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
Antiasthma Drugs: β2-Adrenoceptor Agonists
232
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
232
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
COPD: Management Using Bronchodilators and Corticosteroids
177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177


